The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2024 | Encouraging the integration of bispecifics into routine clinical practice
Amrita Krishnan, MD, City of Hope, Duarte, CA, comments on the integration of bispecifics into community practice, emphasizing the importance of understanding the side effect profile and sequencing with other treatments, as bispecifics are being used in various malignancies, including myeloma, lymphoma, acute myeloid leukemia (AML), and lung cancer. Dr Krishnan notes that while there may be initial trepidation, the side effects of bispecifics are manageable and predictable. This interview took place at the 66th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript (AI-generated)
I think it’s important to put bispecifics in the context and remember how far we’ve come. You know, perhaps 10 years ago or more, we had daratumumab as the first monoclonal antibody for myeloma and a great deal of trepidation about administering that in terms of side effects and now that’s become routine practice. We will get there with bispecifics as well...
I think it’s important to put bispecifics in the context and remember how far we’ve come. You know, perhaps 10 years ago or more, we had daratumumab as the first monoclonal antibody for myeloma and a great deal of trepidation about administering that in terms of side effects and now that’s become routine practice. We will get there with bispecifics as well. So I think the important message that we gave in our seminar this morning was really to get on the train with bispecifics because it’s not just myeloma, it’s lymphoma, AML as well as lung cancer, all have bispecific antibodies, so understanding the side effect profile, which is fairly predictable and manageable, it is important so that you get a degree of comfort because it is something that’s going to be needed for many patients with malignancies.
This transcript is AI-generated. While we strive for accuracy, please verify this copy with the video.
Read more...
